Results
Meta-analysis of Alzheimer's disease GWAS. The Stage 1 discovery meta-analysis produced 12 loci with genome-wide significance (P ≤ 5 × 10 −8 ) ( Table 1) , all of which are previously described 1, [4] [5] [6] [7] [8] [9] [10] [11] . Genomic inflation factors (λ) were slightly inflated (λ median = 1.05; λ regression = 1.09; see Supplementary Figure 2 for a quantile-quantile (QQ) plot); however, univariate linkage disequilibrium score (LDSC) regression 12, 13 estimates indicated that the majority of this inflation was due to a polygenic signal, with the intercept being close to 1 (1.026, s.e.m. = 0.006). The observed heritability (h 2 ) of LOAD was estimated at 0.071 (0.011) using LDSC.
Stage 1 meta-analysis was first followed by Stage 2, using the I-select chip we previously developed in Lambert et al. 1 (including 11,632 variants, n = 18,845; Supplementary Table 4 ) and finally Stage 3A (n = 11,666) or Stage 3B (n = 30,511) (for variants in regions not well captured in the I-select chip) (see Supplementary Figure 1 for the workflow). The final sample was 35,274 clinical and autopsydocumented Alzheimer's disease cases and 59,163 controls.
Meta-analysis of Stages 1 and 2 produced 21 genome-widesignificant associations (P ≤ 5 × 10 −8 ) ( Table 1 and Fig. 1 ), 18 of which were previously reported as genome-wide significant in Lambert et al. 1 . Three other signals were not initially described in the initial IGAP GWAS: the rare R47H TREM2 coding variant previously reported by others 7, 8, 14 ; ECHDC3 (rs7920721; NC_000010.10: g.11720308A>G), which was recently identified as a potential genome-wide-significant Alzheimer's disease risk locus in several studies [15] [16] [17] , and ACE (rs138190086; NC_000017.10: g.61538148G>A) (Supplementary Figs. 3 and 4) . In addition, seven signals showed suggestive association with P < 5 × 10 −7 (closest genes: ADAM10, ADAMTS1, ADAMTS20, IQCK, MIR142/ TSPOAP1-AS1, NDUFAF6, and SPPL2A) . Stage 3A and meta-analysis of all three stages for these nine signals (excluding the TREM2 signal; see Supplementary Table 5 for the variant list) identified five genome-wide-significant loci. In addition to ECHDC3, this included four new genome-wide Alzheimer's disease risk signals at IQCK, ADAMTS1, ACE, and ADAM10 (Table 2) . ACE and ADAM10 were previously reported as Alzheimer's disease candidate genes [18] [19] [20] [21] [22] but were not replicated in some subsequent studies [23] [24] [25] . A recent GWAS using family history of Alzheimer's disease or dementia as a proxy 26 also identified these two risk loci, suggesting that while use of proxy Alzheimer's disease/dementia cases introduces less sensitivity and specificity for true Alzheimer's disease signals overall in comparison to clinically diagnosed Alzheimer's disease, proxy studies can identify diseaserelevant associations. Two of the four other signals approached genome-wide significance: miR142/TSPOAP1-AS1 (P = 5.3 × 10 Table 6 ), suggesting that the genetic variance associated with some GWAS loci is probably underestimated.
We also selected 33 variants from Stage 1 (28 common and 5 rare variants in loci not well captured in the I-select chip; see Methods for full selection criteria) for genotyping in Stage 3B (including populations of Stage 2 and Stage 3A). We nominally replicated a rare variant (rs71618613; NC_000005.9: g.29005985A>C) within an intergenic region near SUCLG2P4 (MAF = 0.01; P = 6.8 × 10
) and replicated a low-frequency variant in the TREM2 region (rs114812713; NC_000006.11: g.41034000G>C, MAF = 0.03, P = 7.2 × 10
) in the gene OARD1 that may represent an independent signal according to our conditional analysis (Table 2, Supplementary Figs. 14  and 15, Supplementary Tables 6 and 7 ). In addition, rs62039712 (NC_000016.9: g.79355857G>A) in the WWOX locus reached genome-wide significance (P = 3.7 × 10 −8
), and rs35868327 (NC_000005.9: g.52665230T>A) in the FST locus reached suggestive significance (P = 2.6 × 10 −7 ) ( Table 2 and Supplementary Figs. 16  and 17) . WWOX may play a role in Alzheimer's disease through its interaction with tau 28, 29 , and it is worth noting that the sentinel variant (defined as the variant with the lowest P value) is just 2.4 megabases from PLCG2, which contains a rare variant that we recently associated with Alzheimer's disease 14 . Since both rs62039712 and rs35868327 were only analyzed in a restricted number of samples, these loci deserve further attention.
Candidate gene prioritization at genome-wide loci. To evaluate the biological significance and attempt to identify the underlying risk genes for the newly identified genome-wide signals (IQCK, ACE, ADAM10, ADAMTS1, and WWOX) and those found previously, we pursued five strategies: (1) annotation and gene-based testing for deleterious coding, loss-of-function (LOF) and splicing variants; (2) expression-quantitative trait loci (eQTL) analyses; (3) evaluation of transcriptomic expression in LOAD clinical traits (correlation with the BRAAK stage 30 and differential expression in Alzheimer's disease versus control brains 31 ); (4) evaluation of transcriptomic expression in Alzheimer's disease-relevant tissues [32] [33] [34] ; and (5) gene cluster/pathway analyses. For the 24 signals reported here, other evidence indicates that APOE 35, 36 , ABCA7 (refs. [37] [38] [39] [40] ), BIN1 (ref. 41 ), TREM2 (refs. 7, 8 ), SORL1 (refs. 42, 43 ), ADAM10 (ref. 44 ), SPI1 (ref. 45 ), and CR1 (ref. 46 ) are the true Alzheimer's disease risk gene, although there is a possibility that multiple risk genes exist in these regions 47 . Because many GWAS loci are intergenic, and the closest gene to the sentinel variant may not be the actual risk gene, in these analyses we considered all protein-coding genes within ±500 kilobases (kb) of the sentinel variant linkage disequilibrium (LD) regions (r 2 ≥ 0.5) for each locus as a candidate Alzheimer's disease gene (n = 400 genes) (Supplementary Table 8) .
We first annotated all sentinel variants for each locus and variants in LD (r 2 > 0.7) with these variants in a search for deleterious coding, LOF or splicing variants. In line with findings that most causal variants for complex disease are non-coding 48 , only 2% of 1,073 variants across the 24 loci (excluding APOE) were exonic variants, with a majority (58%) being intronic ( Supplementary  Fig. 18 and Supplementary Table 9 ). Potentially deleterious variants include the rare R47H missense variant in TREM2, common missense variants in CR1, SPI1, MS4A2, and IQCK, and a relatively common (MAF = 0.16) splicing variant in IQCK. Using results of a large whole-exome-sequencing study conducted in the ADGC and CHARGE sample 49 (n = 5,740 LOAD cases and 5,096 controls), we also identified ten genes located in our genome-wide loci as having rare deleterious coding, splicing or LOF burden associations with LOAD (false discovery rate (FDR) P < 0.01), including previously implicated rare-variant signals in ABCA7, TREM2, and SORL1 (refs. 14, [49] [50] [51] [52] [53] [54] [55] ), and additional associations with TREML4 in the TREM2 locus, TAP2 and PSMB8 in the HLA-DRB1 locus, PIP in the EPHA1 locus, STYX in the FERMT2 locus, RIN3 in the SLC24A4 locus, and KCNH6 in the ACE locus (Supplementary Table 10 ). For eQTL analyses, we searched existing eQTL databases and studies for cis-acting eQTLs in a prioritized set of variants (n = 1,873) with suggestive significance or in LD with the sentinel variant in each locus. ) appears to aid in regulatory variant prioritization, with probabilities for functional variants increasing substantially when using GWAS4D celldependent analyses with brain or monocytes, for instance (these and other annotations are provided in Supplementary Table 11) . Focusing specifically on eQTLs, we found overlapping cis-acting eQTLs for 153 of the 400 protein-coding genes, with 136 eQTLcontrolled genes in Alzheimer's disease-relevant tissues (that is, brain and blood/immune cell types; see Methods for details) (Supplementary Tables 12 and 13 ). For our newly identified loci, there were significant eQTLs in Alzheimer's disease-relevant tissue for ADAM10, FAM63B, and SLTM (in the ADAM10 locus); ADAMTS1 (ADAMTS1 locus); and ACSM1, ANKS4B, C16orf62, GDE1, GPRC5B, IQCK, and KNOP1 (IQCK locus). There were no eQTLs in Alzheimer's disease-relevant tissues in the WWOX or ACE locus, although several eQTLs for PSMC5 in coronary artery tissue were found for the ACE locus. eQTLs for genes in previously identified loci include BIN1 (BIN1 locus), INPP5D (INPP5D locus), CD2AP (CD2AP locus), and SLC24A4 (SLC24A4 locus). Co-localization analysis confirmed evidence of a shared causal variant affecting expression and disease risk in 66 genes over 20 loci, including 31 genes over 13 loci in LOAD-relevant tissue (see Supplementary Table 14 and 15 for complete lists). Genes implicated include CR1 (CR1 locus), ABCA7 (ABCA7 loci), BIN1 (BIN1 locus), SPI1 and MYBPC3 (SPI1 locus), MS4A2, MS4A6A, and MS4A4A (MS4A2 locus), KNOP1 (IQCK locus), and HLA-DRB1 (HLA-DRB1 locus) (Supplementary Table 12 ).
To study the differential expression of genes in brains of patients with Alzheimer's disease versus controls, we used 13 expression studies 31 . We found that 58% of the 400 protein-coding genes within the genome-wide loci had evidence of differential expression in at least one study (Supplementary Table 16 ). Additional comparisons to Alzheimer's disease related gene expression sets revealed that 62 genes were correlated with pathogenic stage (BRAAK) in at least one brain tissue 30 (44 genes in prefrontal cortex, the most relevant LOAD tissue; 36 in cerebellum and 1 in visual cortex). Finally, 38 genes were present in a set of 1,054 genes preferentially expressed in aged microglial cells, a gene set shown to be enriched for Alzheimer's disease genes (P = 4.1 × 10 −5 ) 34 . We also annotated our list of genes with brain RNA-seq data, which showed that 80% were expressed in at least one type of brain cell, and the genes were most highly expressed in fetal astrocytes (26%), followed by microglia/ macrophages (15.8%), neurons (14.8%), astrocytes (11.5%), and oligodendrocytes (6.5%). When not considering fetal astrocytes, mature astrocytes (21%), and microglial cells (20.3%), the resident macrophage cells of the brain thought to play a key role in the pathologic immune response in LOAD 8, 14, 60 , became the highest expressed cell types in the genome-wide set of genes, with 5.3% of the 400 genes showing high microglial expression (Supplementary  Table 17; see Supplementary Table 18 for the highly expressed gene list by cell type).
We conducted pathway analyses (MAGMA
61
) separately for common (MAF > 0.01) and rare variants (MAF < 0.01). For common variants, we detected four function clusters including (1) APP metabolism/Aβ formation (regulation of Aβ formation: P = 4.56 × 10 −7 and regulation of APP catabolic process: P = 3.54 × 10 ) (Table 3  and Supplementary Table 19 ). Enrichment of the four clusters remained after removal of genes in the APOE region. When APOEregion genes and genes near genome-wide-significant genes were removed, tau showed moderate association (P = 0.027), and lipid metabolism and immune-related pathways showed strong associations (P < 0.001) (Supplementary Table 20) . Genes driving these enrichments (that is, having a gene-wide P < 0.05) included SCNA, a Parkinson's risk gene that encodes alpha-synuclein, the main component of Lewy bodies, whch may play a role in tauopathies 62, 63 , for the tau pathway; apolipoprotein genes (APOM, APOA5) and ABCA1, a major regulator of cellular cholesterol, for the lipid metabolism pathways; and 52 immune pathway genes (Supplementary  Table 21 ). While no pathways were significantly enriched for rare variants, lipid and Aβ pathways did reach nominal significance in rare-variant-only analyses. Importantly, we also observed a highly significant correlation between common and rare pathway gene results (P = 1.32 × 10 ), suggesting that risk Alzheimer's disease genes and pathways are enriched for rare variants. In fact, 50 different genes within tau, lipid, immunity and Aβ pathways showed nominal rare-variant driven associations (P < 0.05) with LOAD.
To further explore the APP/Aβ pathway enrichment, we analyzed a comprehensive set of 335 APP metabolism genes 64 curated from the literature. We observed significant enrichment of this gene set in common variants (P = 2.27 × 10
; P = 3.19 × 10 −4 excluding APOE), with both ADAM10 and ACE nominally significant drivers of this result (Table 4 and Supplementary Tables 22 and 23 ). Several 'sub-pathways' were also significantly enriched in the common variants, including 'clearance and degradation of Aβ' , and 'aggregation of Aβ' , along with its subcategory 'microglia' , the latter supporting microglial cells suspected role in response to Aβ in LOAD . Nominal enrichment for risk from rare variants was found for the pathway 'aggregation of Aβ: chaperone' and 23 of the 335 genes.
To identify candidate genes for our novel loci, we combined results from our five prioritization strategies in a priority ranking method similar to that of Fritsche et al. 66 ( Fig. 2 and Supplementary  Table 24 ). ADAM10 was the top ranked gene of the 11 genes within the ADAM10 locus. ADAM10, the most important α-secretase in the brain, is a component of the non-amyloidogenic pathway of APP metabolism 67 and sheds TREM2 (ref.
68
), an innate immunity receptor expressed selectively in microglia. Overexpression of ADAM10 in mouse models can halt Aβ production and subsequent aggregation 69 . In addition, two rare ADAM10 alterations segregating with disease in LOAD families increased Aβ plaque load in ' Alzheimerlike' mice, with diminished α-secretase activity from the alterations probably the causal mechanism 19, 44 . For the IQCK signal, which is also an obesity locus 70, 71 , IQCK, a relatively uncharacterized gene, was ranked top, although four of the other 11 genes in the locus have a priority rank ≥ 4, including KNOP1 and GPRC5B, the latter being a regulator of neurogenesis 72, 73 and inflammatory signaling in obesity 74 . Of the 22 genes in the ACE locus, PSMC5, a key regulator of major histocompatibility complex (MHC) 75, 76 , has a top score of 4, while DDX42, MAP3K3, an important regulator of macrophages and innate immunity 77, 78 , and CD79B, a B lymphocyte antigen receptor subunit, each have a score of 3. Candidate gene studies have associated ACE variants with Alzheimer's disease risk 20, 22, 79 , including a strong association in the Wadi Ara, an Israeli Arab community with high risk of Alzheimer's disease 21 . However, these studies yielded inconsistent results 23 , and our work reports a clear genomewide association in NHW at this locus. While ACE was not prioritized, it should not be rejected as a candidate gene, as its expression in Alzheimer's disease brain tissue is associated with Aβ load and Alzheimer's disease severity 80 . Furthermore, cerebrospinal fluid (CSF) levels of the angiotensin-converting enzyme (ACE) are associated with Aβ levels 81 , being highly expressed in microglia in the Brain RNA-seq database, and WWOX, a high-density-lipoprotein cholesterol and triglyceride-associated gene 94, 95 , being expressed most highly in astrocytes and neurons. WWOX has been implicated in several neurological phenotypes 96 ; in addition, it binds tau and may play a critical role in regulating tau hyper-phosphorylation, neurofibrillary formation and Aβ aggregation 28, 29 . Intriguingly, treatment of mice with its binding partner restores memory deficits 97 , hinting at its potential in neurotherapy. 5) having an eQTL effect on the gene in any tissue, in Alzheimer's disease-relevant tissue, and/ or a co-localized eQTL; (6) being involved in a biological pathway enriched in Alzheimer's disease (from the current study); (7) expression correlated with the BRAAK stage; and (8) differential expression in a 1 + Alzheimer's disease (AD) study. Novel genome-wide loci from the current study are listed first, followed by known genome-wide loci. Each category is assigned an equal weight of 1, with the priority score equaling the sum of all categories. Colored fields indicate that the gene meets the criteria. Genes with a priority score ≥ 4 are listed for each locus. If no gene reached a score of ≥ 5 in a locus, then the top ranked gene(s) is listed.
For previously reported loci, applying the same prioritization approach highlights several genes, as described in Fig. 2 , some of which are involved in APP metabolism (FERMT2, PICALM) or tau toxicity (BIN1, CD2AP, FERMT2, CASS4, PTK2B) [98] [99] [100] [101] . Pathway, tissue and disease trait enrichment analyses support the utility of our prioritization method, as the 53 prioritized genes with a score ≥ 5 are (1) enriched in substantially more Alzheimer's disease-relevant pathways, processes and dementia-related traits; (2) enriched in candidate Alzheimer's disease cell types such as monocytes (adjusted P = 9.0 × 10
) and macrophages (adjusted P = 5.6 × 10 −3 ); and (3) more strongly associated with dementia-related traits and Alzheimer's disease-relevant pathways (Supplementary Table 25 and 26; see Supplementary Fig. 19 for the interaction network of these prioritized genes). To further investigate the cell types and tissues the prioritized genes are expressed in, we performed differentially expressed gene (DEG) set enrichment analysis of the prioritized genes by using GTEx 102 tissues, and we identified significant differential expression in several potentially relevant Alzheimer's disease tissues including immune-related tissues (upregulation in blood and spleen), obesity-related tissue (upregulation in adipose), heart tissues (upregulation in left ventricle and atrial appendage), and brain tissues (dowregulation in cortex, cerebellum, hippocampus, basal ganglia, and amygdala). Furthermore, the 53 genes are overexpressed in 'adolescence' and 'young adult' brain tissues in BrainSpan
103
, a transcriptomic atlas of the developing human brain, which is consistent with accumulating evidence suggesting Alzheimer's disease may start decades before the onset of disease 104, 105 (Supplementary Fig. 20 ; see Supplementary Fig. 21 for a tissue expression heat map for the 53 genes).
Fine-mapping of the HLA region. The above approach prioritized HLA-DRB1 as the top candidate gene in the MHC locus, known for its complex genetic organization and highly polymorphic nature (see Supplementary Fig. 22 for a plot of the region of the Stage 1 results). Previous analyses in the ADGC (5,728 Alzheimer's disease cases and 5,653 controls) have linked both HLA class I and II haplotypes with Alzheimer's disease risk 106 . In order to further investigate this locus in a much larger sample, we used a robust imputation method and fine-mapping association analysis of alleles and haplotypes of HLA class I and II genes in 14,776 cases and 23,047 controls from our datasets (Supplementary Table 27 ). We found risk effects of HLA-DQA1*01:02 (FDR P = 0.014), HLA-DRB1*15:01 (FDR P = 0.083), and HLA-DQB1*06:02 (FDR P = 0.010) (Supplementary Table 28 ). After conditioning on the sentinel meta-analysis variant in this region (rs78738018), association signals were lost for the three alleles, suggesting that the signal observed at the variant level is due to the association of these three alleles. These alleles form the HLA-DQA1*01:02~HLA-DQB1*06:02~HLA-DRB1*15:01 (DR15) haplotype, which is also associated with Alzheimer's disease in our sample (FDR P = 0.013) (Supplementary Table 29 ). Taken together, these results suggest a central role of the DR15 haplotype in Alzheimer's disease risk, a finding originally discovered in a small study in the Tunisian population 107 and more recently in a large ADGC analysis 106 . Intriguingly, the DR15 haplotype and its component alleles also associate with protection against diabetes 108 , a high risk for multiple sclerosis 109, 110 , and risk or protective effects with many other immune-mediated diseases (Supplementary  Table 30 ). Moreover, the associated diseases include a large number of traits queried from an HLA-specific Phewas 111 , including neurological diseases (for example, Parkinson's disease 112, 113 ) and diseases with risk factors for Alzheimer's disease (for example, hyperthyroidism 114 ), pointing to potential shared and/or interacting mechanisms and co-morbidities, a common paradigm in the MHC locus 115 . Two additional alleles, HLA-DQA1*03:01 and HLA-DQB1*03:02, belonging to another haplotype, show a protective effect on Alzheimer's disease, but their signal was lost after conditioning on HLA-DQA1*01:02, and the HLA-DQA1*03:01~HLA-DQB1*03:02 haplotype is not associated with Alzheimer's disease (FDR P = 0.651).
Genetic correlations with Alzheimer's disease. As described above, several of our genome-wide loci have potentially interesting co-morbid or pleiotropic associations with traits that may be relevant to the pathology of Alzheimer's disease. To investigate the extent of LOAD's shared genetic architecture with other traits, we performed LD-score regression to estimate the genetic correlation between LOAD and 792 human diseases, traits and behaviors 12, 116 (Supplementary Table 31 ). The common variant genetic architecture of LOAD was positively correlated with a maternal family history of Alzheimer's disease/dementia (r g for the genetic correlation of two traits = 0.81; FDR P = 2.79 × 10 ), similar to the Marioni et al. family proxy analyses 26 , which found maternal genetic correlation with Alzheimer's disease to be higher than that for paternal Alzheimer's disease (r g = 0.91 and 0.66, respectively). There is substantial overlap between these estimates, as the Marioni et al. analyses include the 2013 IGAP summary statistics and employed the same UK Biobank variable that we used for r g estimates with maternal history of dementia. We also find significant negative correlation between Alzheimer's disease and multiple measures of educational attainment (for example, college completion, r g = −0.24; years of schooling, r g range = −0.19 to −0.24; cognitive scores, r g = −0.24 and −0.25) (FDR P < 0.05), supporting the theory that a greater cognitive reserve could help protect against development of LOAD
117
. The extent to which socioeconomic, environmental, or cultural factors contribute to the correlation between educational attainment and risk for Alzheimer's disease is unknown, but research shows dementia risk to be associated with lower socioeconomic status, independently of education status 118, 119 . We also found negative correlations at P < 0.05 with multiple measures of cardiovascular health (that is, family history of high blood pressure and heart disease and vascular/heart problems) and diabetes (that is, fasting proinsulin, basal metabolic rate and fasting insulin), supporting previous research suggesting that use of blood pressure and diabetic medications may reduce the risk of Alzheimer's disease 120 . In fact, use of blood pressure medication does show a negative genetic correlation with Alzheimer's disease in our study (r g = −0.12; P = 0.035), although this result does not survive FDR correction. These and other top results from this analysis (for example, body mass index, height; see Supplementary Table 31 for a full list of other nominally significant correlations) have been linked to Alzheimer's disease previously 116, [120] [121] [122] [123] [124] [125] [126] [127] , either through suggestive or significant genetic or epidemiological associations (see Kuzma et al. 128 for a recent review), but the multiple measures here support and emphasize their genetic correlation with LOAD and highlight the possible genetic pleiotropy or co-morbidity of these traits with pathology of LOAD.
Discussion
In conclusion, our work identifies five new genome-wide associations for LOAD and shows that GWAS data combined with highquality imputation panels can reveal rare disease risk variants (for example, TREM2). The enrichment of rare variants in pathways associated with Alzheimer's disease indicates that additional rare variants remain to be identified, and larger samples and better imputation panels will facilitate identifying them. While these rare variants may not contribute substantially to the predictive value of genetic findings, they will enhance the understanding of disease mechanisms and potential drug targets. Discovery of the risk genes at genome-wide loci remains challenging, but we demonstrate that converging evidence from existing and new analyses can prioritize risk genes. We also show that APP metabolism is associated with not only early-onset Alzheimer's disease but also LOAD, suggest-ing that therapies developed by studying early-onset families could also be applicable to the more common late-onset form of the disease. Pathway analysis showing that tau is involved in LOAD supports recent evidence that tau may play an early pathological role in Alzheimer's disease [129] [130] [131] and confirms that therapies targeting tangle formation/degradation could potentially affect LOAD. Finally, our fine-mapping analyses of HLA and genetic correlation results point to LOAD's shared genetic architecture with many immunemediated and cognitive traits, suggesting that research and interventions that elucidate mechanisms behind these relationships could also yield fruitful therapeutic strategies for LOAD. 
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Sample size
We did not collect our sample for this study based on a calculated sample size. The study represent the largest study to date of diagnosed Alzheimer's disease and includes samples from the four largest Alzheimer disease consortia. For GWAS studies, current practice is to include as many samples in a study as possible, regardless of sample size, especially given the desire to increase power for finding association with rare variants. We did calculate sample sizes we would need in order to have enough power to find an association with rare variants. This analysis is available and we can include it in the Supplementary information or methods if requested.
Data exclusions We exluded samples and variants based on standard quality control procedures for GWAS. Details of our quality control procedures are provided in the methods section of the manuscript.
Replication
Given that current practice for analyzing GWAS is to include as many samples as possible in the discovery analysis, we did not perform a traditional replication analysis. We did however use a strategy which allowed for genotyping/sequencing of our top results from our stage 1 discovery in large independent samples for our Stage 2 and 3 analyses. These Stages were then combined in meta-analysis. In addition, we confirmed 18 of the 20 loci from our previous 2013 GWAS using a larger sample size.
